Impact of skin cancer screening on the incidence of advanced melanoma and melanoma mortality – A pilot project for a case-control study in the setting of the German nationwide skin cancer screening

Impact of skin cancer screening on the incidence of advanced melanoma and melanoma mortality – A pilot project for a case-control study in the setting of the German nationwide skin cancer screening - PiKoM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012831

Enrollment

Registered

2017-11-14

Start date

2018-02-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C43

Interventions

Group 1: Advanced melanoma patients with stage IV melanoma at time of recruitment will be interviewed after inclusion (at one time) about skin cancer early detection activities in the past. We will co

Eligibility

Sex/Gender

All

Age

37 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria for cases: Primary diagnosis of invasive cutaneous melanoma (ICD-10: C43); Stage IV disease at time of recruitment (irrespective of stage at diagnosis); Date of first diagnosis in 2013 or later; Age at first diagnosis =37 years; Informed written consent for study participation. Inclusion criteria for controls: Age, sex and region matched to the corresponding case; Informed written consent for study participation.

Exclusion criteria

Exclusion criteria: Exclusion criteria of cases: Age at first diagnosis 36 years and younger; Second melanoma; Inability to take part in the questionnaire or telephone interview; Inability to take part in skin cancer screening before melanoma diagnosis (e.g. living abroad); No informed written consent. Exclusion criteria of controls: Age, sex, and region not compatible with the corresponding case; Inability to take part in the questionnaire or telephone interview; Inability to take part in skin cancer screening before melanoma diagnosis (e.g. living abroad); No informed written consent.

Design outcomes

Primary

Measure	Time frame
Feasibility of a case-control study for evaluating effects of skin cancer screenig.	—

Countries

Germany

Contacts

Public ContactAlicia Brunssen

Institute for Social Medicine and Epidemiology, University of Lübeck, Germany

alicia.brunssen@uksh.de+49 451 50051210

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026